Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, USA.
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ann Surg Oncol. 2019 Aug;26(8):2357-2366. doi: 10.1245/s10434-019-07351-6. Epub 2019 Apr 22.
The median age at diagnosis for malignant pleural mesothelioma (MPM) is approximately 72 years. Elderly patients pose unique management challenges because of the increased risk of therapy-related toxicities and mortality. Because there are no high-volume retrospective studies, prospective trials, or dedicated treatment recommendations for this population, this investigation addresses a major knowledge gap by examining national practice patterns and postoperative/survival outcomes in elderly MPM patients.
The National Cancer Database was queried for patients aged ≥ 80 years with newly diagnosed nonmetastatic MPM. Multivariable logistic regression ascertained factors associated with observation and surgery. Kaplan-Meier analysis assessed overall survival (OS), and multivariable Cox proportional hazards modeling examined factors associated with OS. Survival was also calculated following propensity matching. Additionally, postoperative outcomes were evaluated in surgical patients.
Of 4526 patients, 2% received surgery and chemotherapy, 22% underwent chemotherapy alone, and 63% were observed. Respective median OS was 12.2, 9.5, and 4.1 months (p < 0.001). Differences between all groups persisted following propensity matching (all comparisons p < 0.05). For the 8% of patients who underwent specified definitive surgery (95% of whom received pleurectomy/decortication), 30- and 90-day mortality rates were 11.0% and 28.5%, respectively. The median length of postoperative hospitalization was 6 days, with 30-day readmission occurring in 7.5% of patients.
The majority of elderly MPM patients in the US are observed, which was associated with poorer OS than chemotherapy and/or surgery. Although highly selected surgery/chemotherapy patients were associated with the longest OS, given the high biases in database studies and high perioperative mortality rates, careful patient selection for combined modality approaches in this population is imperative.
恶性胸膜间皮瘤(MPM)的中位诊断年龄约为 72 岁。由于治疗相关毒性和死亡率增加,老年患者存在独特的管理挑战。由于缺乏针对该人群的大样本回顾性研究、前瞻性试验或专门的治疗建议,因此本研究通过检查老年 MPM 患者的全国实践模式和术后/生存结果,解决了一个主要的知识空白。
国家癌症数据库中检索了年龄≥80 岁、新诊断为非转移性 MPM 的患者。多变量逻辑回归确定了与观察和手术相关的因素。采用 Kaplan-Meier 分析评估总生存期(OS),并采用多变量 Cox 比例风险模型分析与 OS 相关的因素。在进行倾向匹配后,还计算了生存率。此外,还评估了手术患者的术后结果。
在 4526 名患者中,2%接受了手术和化疗,22%仅接受了化疗,63%接受了观察。相应的中位 OS 分别为 12.2、9.5 和 4.1 个月(p<0.001)。在进行倾向匹配后,所有组之间的差异仍然存在(所有比较 p<0.05)。对于接受指定确定性手术的 8%的患者(其中 95%接受了胸膜切除术/剥脱术),30 天和 90 天死亡率分别为 11.0%和 28.5%。术后住院时间中位数为 6 天,30 天内再入院率为 7.5%。
美国大多数老年 MPM 患者处于观察状态,其 OS 比化疗和/或手术差。尽管高度选择的手术/化疗患者与最长的 OS 相关,但鉴于数据库研究中的高度偏倚和围手术期死亡率高,在该人群中选择联合治疗方法需要仔细考虑患者。